The MSSO has discontinued maintenance of the Paediatric and Gender Adverse Event Term Lists as of MedDRA Version 19.0.  The lists and supporting documentation are archived below for reference.

Paediatric and Gender Adverse Event Term Lists (Archived as of MedDRA Version 19.0)

Paediatric Adverse Event Term List

Description
Medicinal products may affect physical and cognitive growth and development, and the adverse event profile may differ in paediatric patients. Because developing systems may respond differently than mature adult organs, some adverse events and drug interactions that occur in paediatric patients may not be identified in adult studies and therefore need specific monitoring. In addition, the dynamic processes of growth and development may not manifest adverse events acutely, but at a later stage of growth and maturation and therefore also require monitoring.

Supporting Documentation 
Paediatric Adverse Events in MedDRA (pdf)

Term List 
Paediatric Adverse Events in MedDRA (MedDRA Version 19.0) (.xlsx)

Gender Adverse Event Term List

Description
These are separate lists for male and female terms. Besides a potential use in monitoring gender-specific adverse events, the gender term lists are also intended as a query to validate coding at the data entry level by highlighting reports that include gender inconsistencies (e.g., female patients with prostate cancer).

Supporting Documentation 
Gender Adverse Events in MedDRA (pdf)

Term List 
Gender Specific Adverse Event Term List (MedDRA Version 19.0) (.xlsx)